Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial

NCT07106034 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: Ongericimab + Toripalimab + Bevacizumab + FOLFOX
DRUG: Ongericimab + Toripalimab + Bevacizumab + FOLFIRI

Sponsor

Shanghai Pudong Hospital

Collaborators

[object Object]